Cargando…
Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data
The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could imp...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640717/ https://www.ncbi.nlm.nih.gov/pubmed/36344529 http://dx.doi.org/10.1038/s41541-022-00538-1 |
_version_ | 1784825921532854272 |
---|---|
author | Ryman, Josiah Weaver, Jessica Hu, Tianyan Weinberger, Daniel M. Yee, Ka Lai Sachs, Jeffrey R. |
author_facet | Ryman, Josiah Weaver, Jessica Hu, Tianyan Weinberger, Daniel M. Yee, Ka Lai Sachs, Jeffrey R. |
author_sort | Ryman, Josiah |
collection | PubMed |
description | The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could impact effectiveness. Simulated reverse cumulative distribution curves were generated using published serotype-specific IgG concentrations with placebo or PCV7. This was combined with the published estimates of serotype-specific vaccine effectiveness of PCV7 against invasive pneumococcal disease to estimate the protective antibody concentration for each serotype in PCV7. Then, based on the published serotype-specific IgG concentrations in PCV13 recipients, reverse cumulative distribution curves were generated for the serotypes shared between PCV13 and PCV7. These estimated protective antibody concentration values were then used to predict the vaccine effectiveness of PCV13. The results were compared to published aggregate values for vaccine effectiveness. The aggregate median predicted vaccine effectiveness values were similar to previously reported observed values for the United Kingdom (93% versus 90%), Australia (71% versus 70%), and Germany (91% versus 90%). These results demonstrate that IgG concentrations of next-generation PCVs can be used to generate reliable estimates of vaccine effectiveness for serotypes shared with established PCVs. |
format | Online Article Text |
id | pubmed-9640717 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-96407172022-11-15 Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data Ryman, Josiah Weaver, Jessica Hu, Tianyan Weinberger, Daniel M. Yee, Ka Lai Sachs, Jeffrey R. NPJ Vaccines Article The strength of the immune response, as measured by antibody concentrations, varies between pneumococcal conjugate vaccines (PCVs). Linking immunogenicity and effectiveness is necessary to assess whether changes in immune response from currently recommended PCVs to next-generation vaccines could impact effectiveness. Simulated reverse cumulative distribution curves were generated using published serotype-specific IgG concentrations with placebo or PCV7. This was combined with the published estimates of serotype-specific vaccine effectiveness of PCV7 against invasive pneumococcal disease to estimate the protective antibody concentration for each serotype in PCV7. Then, based on the published serotype-specific IgG concentrations in PCV13 recipients, reverse cumulative distribution curves were generated for the serotypes shared between PCV13 and PCV7. These estimated protective antibody concentration values were then used to predict the vaccine effectiveness of PCV13. The results were compared to published aggregate values for vaccine effectiveness. The aggregate median predicted vaccine effectiveness values were similar to previously reported observed values for the United Kingdom (93% versus 90%), Australia (71% versus 70%), and Germany (91% versus 90%). These results demonstrate that IgG concentrations of next-generation PCVs can be used to generate reliable estimates of vaccine effectiveness for serotypes shared with established PCVs. Nature Publishing Group UK 2022-11-07 /pmc/articles/PMC9640717/ /pubmed/36344529 http://dx.doi.org/10.1038/s41541-022-00538-1 Text en © Merck & Co., Inc., Rahway, NJ, USA and its affiliates 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Ryman, Josiah Weaver, Jessica Hu, Tianyan Weinberger, Daniel M. Yee, Ka Lai Sachs, Jeffrey R. Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
title | Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
title_full | Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
title_fullStr | Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
title_full_unstemmed | Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
title_short | Predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
title_sort | predicting vaccine effectiveness against invasive pneumococcal disease in children using immunogenicity data |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9640717/ https://www.ncbi.nlm.nih.gov/pubmed/36344529 http://dx.doi.org/10.1038/s41541-022-00538-1 |
work_keys_str_mv | AT rymanjosiah predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata AT weaverjessica predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata AT hutianyan predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata AT weinbergerdanielm predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata AT yeekalai predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata AT sachsjeffreyr predictingvaccineeffectivenessagainstinvasivepneumococcaldiseaseinchildrenusingimmunogenicitydata |